Welcome to International Network for Natural Sciences | INNSpub

Simultaneous increased Inteleukine-6 and decreased glucose concentration in response to a single bout cycling exercise

Research Paper | April 1, 2011

| Download 4

Eizadi Mojtaba, Parsian Heshmatolah, Faraji Gholamreza, Zand Alireza

Key Words:

J. Bio. Env. Sci.1( 2), 45-51, April 2011


JBES 2011 [Generate Certificate]


Pro-inflammatory cytokine interleukin-6 (IL-6) is known to play important role in glucose homeostasis. To investigate serum IL-6 response to acute exercise and to determine the relationship between Changes in its levels with changes in glucose concentration in response to exercise. Venous blood samples were obtained before and after a single bout incremental cycling test in order to measuring serum IL-6 and glucose concentration in eighteen none-trained adult overweight or obese men (26 ≤ BMI ≤ 33 kg/m2, 38 ± 6 years). Statistic analysis was done with SPSS 15.0 for Windows using by paired samples T-test and Pearson methods. Cycling exercise test resulted in significant increase in serum IL-6 (p = 0.021) and significant decrease in glucose concentration (p = 0.033). In response to exercise test, Changes in serum IL-6 was negatively correlated with change in glucose concentration (p = 000, r = -0.74). These finding suggest the anti-inflammatory effect of single bout exercise on glucose homeostasis.


Copyright © 2011
By Authors and International Network for
Natural Sciences (INNSPUB)
This article is published under the terms of the Creative
Commons Attribution Liscense 4.0

Simultaneous increased Inteleukine-6 and decreased glucose concentration in response to a single bout cycling exercise

Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G. 2006. Interleukin-6 Increases Insulin-Stimulated Glucose Disposal in Humans and Glucose Uptake and Fatty Acid Oxidation In Vitro via AMP-Activated Protein Kinase. Diabetes 55(10), 2688-97.

Carey AL, Steinberg GR, Macaulay SL. 2006. IL-6 increases insulin stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMPK. Diabetes 55, 2688-2697.

Choy EH, Isenberg DA, Garrood T. 2002. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46, 3143-3150.

Fisher JS, Gao J, Han DH, Holloszy JO, Nolte LA. 2002. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab 282, 18–23.

Hotamisligil GS. 2006. Inflammation and metabolic disorders. Nature 444, 860–867.

Hu G, Tuomilehto J, Silventoinen K, Barengo NC, Peltonen M, Jousilahti P. 2005. The effects of physical activity and body mass index on cardiovascular, cancer and all-cause mortality among 47 212 middle-aged Finnish men and women. Int J Obes Relat Metab Disord 8, 894-902.

Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE. 2001. 5 -AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem 276, 46912– 46916.

Julia W, Karen C, Javier R, Ascension M. 2010. Role of physical activity on immune function Physical activity, exercise and low-grade systemic inflammation. Proceedings of the Nutrition Society 69, 400–406.

Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X. 2004. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320, 449–454.

Kopp HP, Kopp CW, Festa A. 2003. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23, 1042-7.

Lamonte  MJ,  Blair  SN,  Church  TS.  2005. Physical activity and diabetes prevention. J Appl Physiol 99, 1205-1213.

Libby P. 2006. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83, 456S–460S.

Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H. 2010. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor {alpha} expression. Gut 59(9), 1259-64.

Mullis R, Campbell IT, Wearden AJ, Morriss RK, Pearson DJ. 1999. Prediction of peak oxygen uptake in chronic fatigue syndrome. British Journal of Sports Medicine 33(5), 352-6.

Nishimoto N, Yoshizaki K, Miyasaka N. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50, 1761-1769.

Ontana L, Eagon JC,      Trujillo ME. 2007. Visceral  fat  adipokine  secretion  is  associated  with systemic inflammation in obese humans. Diabetes 56, 1010-13.

Ostrowski K, Rohde T, Zacho M. 1998. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 508 (3), 949–953.

Pedersen BK, Steensberg A, Fischer C. 2003. Searching for the exercise factor – is IL-6 a candidate. J Muscle Res Cell Motil 24, 113-119.

Petersen AM, Pedersen BK. 2006. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57(10), 43-51.

Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, Pedersen BK. 2005. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288, 155–162.

Philippou A, Bogdanis G, Maridaki M. 2009. Systemic cytokine response following exercise-induced muscle damage in humans. Clin Chem Lab Med 47, 777–782.

Rotter V, Nagaev I, Smith U. 2003. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278, 45777-84.

Rotter V, Nagaev I, Smith U. 2003. Interleukin-6 (IL-6) induces insulin resistance in 3T3–L1 adipocytes and is, like IL-8 and TNFalpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278, 45777–45785.

Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK. 2003. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 285, 433-437.

Stouthard JM, Oude Elferink RP, Sauerwein HP. 1996. Interleukin-6 enhances glucose transport in 3T3–L1 adipocytes. Biochem Biophys Res Commun220, 241–245.

Thune I, Furberg AS. 2001. Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med Sci Sports Exerc 33, 530-550.

Machicao F, Haring HU, Schleicher ED. 2004. Weigert C, Brodbeck K, Staiger H, Kausch C, Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome dependent activation of nuclear factor-kappaB. J Biol Chem 279, 23942–23952.